Habil Khorakiwala-led health care major Wockhardt is planning to globally introduce antibiotics that may help contain the problem of anti-microbial drug resistance. The Mumbai-based drug maker has sought the Centre’s intervention to seek funding from G-20 countries, an international forum of governments for development of the portfolio, a top government official told Business Standard. The antibiotic has been in the making for the last two decades. Currently, it’s learnt to be at an advanced stage of development. While the investment made ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?